KR102616970B1 - Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물 - Google Patents
Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물 Download PDFInfo
- Publication number
- KR102616970B1 KR102616970B1 KR1020197030311A KR20197030311A KR102616970B1 KR 102616970 B1 KR102616970 B1 KR 102616970B1 KR 1020197030311 A KR1020197030311 A KR 1020197030311A KR 20197030311 A KR20197030311 A KR 20197030311A KR 102616970 B1 KR102616970 B1 KR 102616970B1
- Authority
- KR
- South Korea
- Prior art keywords
- solvate
- hydrate
- salt
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704327.4A GB201704327D0 (en) | 2017-03-17 | 2017-03-17 | Compounds |
| GB1704327.4 | 2017-03-17 | ||
| PCT/EP2018/056663 WO2018167269A1 (en) | 2017-03-17 | 2018-03-16 | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190129936A KR20190129936A (ko) | 2019-11-20 |
| KR102616970B1 true KR102616970B1 (ko) | 2023-12-22 |
Family
ID=58688233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197030311A Active KR102616970B1 (ko) | 2017-03-17 | 2018-03-16 | Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11485731B2 (https=) |
| EP (1) | EP3596061B1 (https=) |
| JP (1) | JP7211982B2 (https=) |
| KR (1) | KR102616970B1 (https=) |
| CN (1) | CN110650950B (https=) |
| AU (2) | AU2018235139A1 (https=) |
| CA (1) | CA3056724A1 (https=) |
| GB (1) | GB201704327D0 (https=) |
| IL (1) | IL269354B2 (https=) |
| MX (1) | MX2019011061A (https=) |
| NZ (1) | NZ757500A (https=) |
| SG (1) | SG11201908598PA (https=) |
| WO (1) | WO2018167269A1 (https=) |
| ZA (1) | ZA201906269B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| EP3980406A4 (en) * | 2019-06-06 | 2023-06-28 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
| CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
| US12595248B2 (en) | 2019-12-17 | 2026-04-07 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| JP7589247B2 (ja) | 2019-12-17 | 2024-11-25 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｒｍｔ５阻害剤 |
| JP7507892B2 (ja) * | 2020-06-02 | 2024-06-28 | 石薬集団中奇制薬技術（石家庄）有限公司 | ３，４－ジヒドロイソキノリン系化合物及びその使用 |
| PH12022553378A1 (en) | 2020-06-10 | 2024-03-25 | Univ Leuven Kath | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| AU2021300483A1 (en) * | 2020-06-30 | 2023-02-09 | Nanjing Zaiming Pharmaceutical Co., Ltd. | Tetrahydroisoquinoline compounds and use thereof |
| CN116113626B (zh) | 2020-09-04 | 2025-10-10 | 上海翊石医药科技有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| IL305165A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| US12600721B2 (en) | 2021-02-19 | 2026-04-14 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| CA3207819A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| CN115340528A (zh) | 2021-05-13 | 2022-11-15 | 上海翊石医药科技有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
| JP2024525589A (ja) | 2021-07-09 | 2024-07-12 | アリゴス セラピューティクス インコーポレイテッド | 抗ウイルス化合物 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| US20250051307A1 (en) * | 2021-12-08 | 2025-02-13 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang) Co., Ltd | Salt of 3,4-dihydroisoquinoline compound and use thereof |
| WO2023125947A1 (zh) * | 2021-12-30 | 2023-07-06 | 江苏先声药业有限公司 | 四氢异喹啉类化合物的可药用盐、晶型及其用途 |
| WO2023131305A1 (zh) * | 2022-01-06 | 2023-07-13 | 江苏先声药业有限公司 | Prmt5抑制剂和抗癌治疗剂的组合 |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2015200677A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| JP2016511744A (ja) * | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
-
2017
- 2017-03-17 GB GBGB1704327.4A patent/GB201704327D0/en not_active Ceased
-
2018
- 2018-03-16 NZ NZ757500A patent/NZ757500A/en unknown
- 2018-03-16 CA CA3056724A patent/CA3056724A1/en active Pending
- 2018-03-16 CN CN201880032332.4A patent/CN110650950B/zh active Active
- 2018-03-16 EP EP18714178.3A patent/EP3596061B1/en active Active
- 2018-03-16 KR KR1020197030311A patent/KR102616970B1/ko active Active
- 2018-03-16 IL IL269354A patent/IL269354B2/en unknown
- 2018-03-16 US US16/494,532 patent/US11485731B2/en active Active
- 2018-03-16 SG SG11201908598P patent/SG11201908598PA/en unknown
- 2018-03-16 WO PCT/EP2018/056663 patent/WO2018167269A1/en not_active Ceased
- 2018-03-16 AU AU2018235139A patent/AU2018235139A1/en not_active Abandoned
- 2018-03-16 MX MX2019011061A patent/MX2019011061A/es unknown
- 2018-03-16 JP JP2019571788A patent/JP7211982B2/ja active Active
-
2019
- 2019-09-23 ZA ZA2019/06269A patent/ZA201906269B/en unknown
-
2022
- 2022-04-11 AU AU2022202389A patent/AU2022202389B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2015200677A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022202389B2 (en) | 2024-04-18 |
| EP3596061A1 (en) | 2020-01-22 |
| JP2020510091A (ja) | 2020-04-02 |
| US20200325128A1 (en) | 2020-10-15 |
| AU2022202389A1 (en) | 2022-05-05 |
| EP3596061C0 (en) | 2023-09-06 |
| MX2019011061A (es) | 2019-12-19 |
| IL269354B2 (en) | 2023-11-01 |
| NZ757500A (en) | 2026-03-27 |
| KR20190129936A (ko) | 2019-11-20 |
| SG11201908598PA (en) | 2019-10-30 |
| CN110650950B (zh) | 2023-09-19 |
| CA3056724A1 (en) | 2018-09-20 |
| JP7211982B2 (ja) | 2023-01-24 |
| ZA201906269B (en) | 2024-03-27 |
| EP3596061B1 (en) | 2023-09-06 |
| BR112019019358A2 (pt) | 2020-04-14 |
| CN110650950A (zh) | 2020-01-03 |
| US11485731B2 (en) | 2022-11-01 |
| IL269354B1 (en) | 2023-07-01 |
| GB201704327D0 (en) | 2017-05-03 |
| IL269354A (en) | 2019-11-28 |
| WO2018167269A1 (en) | 2018-09-20 |
| AU2018235139A1 (en) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102616970B1 (ko) | Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물 | |
| JP7781244B2 (ja) | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 | |
| KR102604942B1 (ko) | 증식성 장애의 치료에 사용하기 위한 트리사이클릭 화합물 | |
| EP3630749B1 (en) | 2-quinolone derived inhibitors of bcl6 | |
| WO2023061415A1 (en) | Thiadiazolyl derivatives, compositions and uses thereof | |
| WO2022185041A1 (en) | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | |
| WO2022258986A1 (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| ES2845048T3 (es) | Preparación y usos de derivados de pirimidinona | |
| WO2021084265A1 (en) | Isoquinoline derivatives as sik2 inhibitors | |
| BR112019019358B1 (pt) | Compostos, composição farmacêutica, uso dos referidos compostos, método in vitro para alterar a expressão gênica em uma célula e combinação compreendendo um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191015 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210304 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230510 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20231023 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20231219 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20231219 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |